WST Share Price | West Pharmaceutical Services, Inc. Stock Analysis & Recommendation

Q: How big is West Pharmaceutical Services, Inc.?

Market Cap: As of Jun 18, West Pharmaceutical Services, Inc. has a market capitalization of 15,928.27 million, categorizing it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, West Pharmaceutical Services, Inc. reported net sales of 2,895.60 million and a net profit of 467.20 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 2,682.30 million and total assets of 3,643.40 million.

Q: What does West Pharmaceutical Services, Inc. do?

Overview: West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.Financial Snapshot: Net Sales: 698 Million (Quarterly Results - Mar 2025) Net Profit: 90 Million (Quarterly Results - Mar 2025) Market-cap: USD 15,928.27 Million (Large Cap)Key Metrics: P/E: 33.00 Dividend Yield: 0.38% Debt Equity: -0.07 Return on Equity: 18.49% Price to Book: 5.94Contact Details: Address: 530 HERMAN O WEST DR, EXTON PA: 19341-1147 Tel: ['1 610 5942900', '1 610 5943318'] Fax: 1 800 3459800 Website: https://www.westpharma.com/

Q: Is West Pharmaceutical Services, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for West Pharmaceutical Services, Inc. has changed from mildly bearish to bullish. The weekly MACD is bullish, and the monthly RSI is also bullish, indicating positive momentum. Daily moving averages are bullish, supporting the upward trend. However, the monthly KST is bearish, and the OBV shows a mildly bearish trend on the weekly timeframe, which suggests some caution. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 2.98% and 6.92% respectively, while the S&P 500 returned 1.09% and 4.15%. However, the year-to-date and one-year returns are negative at -18.16% and -9.59%, significantly lagging behind the S&P 500's positive returns of 14.18% and 17.82%. Overall, the current stance is bullish, but with mixed signals that indicate a need for careful monitoring.

Q: Is West Pharmaceutical Services, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43, all of which are higher than many of its peers. For instance, Edwards Lifesciences Corp. has a P/E of 31.17 and an EV to EBITDA of 26.51, while Agilent Technologies, Inc. shows a more favorable P/E of 27.42 and an EV to EBITDA of 20.75.Despite recent short-term performance, where West Pharmaceutical outperformed the S&P 500 with a 1-week return of 3.37% compared to 1.70%, the longer-term outlook is concerning, with a year-to-date return of -17.39% versus the S&P 500's 13.30%. This trend suggests that while the stock may have some short-term momentum, its overall valuation metrics indicate it is not justified at current levels.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

867.79 k

Shareholding (Dec 2025)

FII

31.06%

Held by 384 FIIs

DII

26.31%

Held by 53 DIIs

Promoter

0.03%

How big is West Pharmaceutical Services, Inc.?

22-Jun-2025

As of Jun 18, West Pharmaceutical Services, Inc. has a market capitalization of $15.93 billion, with net sales of $2.90 billion and a net profit of $467.20 million over the latest four quarters. The company reported shareholder's funds of $2.68 billion and total assets of $3.64 billion as of Dec 24.

View full answer

What does West Pharmaceutical Services, Inc. do?

22-Jun-2025

West Pharmaceutical Services, Inc. manufactures packaging components and delivery systems for injectable drugs, with net sales of $698 million and a market cap of approximately $15.93 billion as of March 2025. Key financial metrics include a P/E ratio of 33.00 and a dividend yield of 0.38%.

View full answer

Who are in the management team of West Pharmaceutical Services, Inc.?

22-Jun-2025

As of March 2022, the management team of West Pharmaceutical Services, Inc. includes Patrick Zenner (Independent Chairman), Eric Green (CEO), and several Independent Directors: Mark Buthman, William Feehery, Robert Friel, Thomas Hofmann, and Paula Johnson. They are responsible for the company's strategic direction and operations.

View full answer

Is West Pharmaceutical Services, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, but mixed signals suggest caution due to recent underperformance compared to the S&P 500.

View full answer

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, West Pharmaceutical Services, Inc. is considered overvalued with a valuation grade of "expensive," reflected in its high P/E ratio of 33 and poor long-term performance, despite recent short-term gains.

View full answer

Compare West Pharmaceutical Services, Inc. with Similar Stocks

GE Healthcare Technologies, Inc.Agilent Technologies, Inc.IDEXX Laboratories, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 22.89%

Company has a low Debt to Equity ratio (avg) at times

Healthy long term growth as Operating profit has grown by an annual rate 12.66%

Flat results in Jun 25

With ROE of 18.49%, it has a fair valuation with a 6.12 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 17,596 Million (Mid Cap)

P/E

33.00

Industry P/E

Dividend Yield

0.36%

Debt Equity

-0.18

Return on Equity

16.61%

Price to Book

5.54

Revenue and Profits:

Net Sales:

806 Million

(Quarterly Results - Dec 2025)

Net Profit:

132 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-9.81%

6 Months

-6.98%

1 Year

4.43%

2 Years

-38.0%

3 Years

-28.57%

4 Years

-39.43%

5 Years

-12.35%

West Pharmaceutical Services, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.45%

EBIT Growth (5y)

8.59%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

0.97

Tax Ratio

20.26%

Dividend Payout Ratio

12.66%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

32.01%

ROE (avg)

22.89%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.54

EV to EBIT

26.75

EV to EBITDA

21.08

EV to Capital Employed

6.52

EV to Sales

5.54

PEG Ratio

7.57

Dividend Yield

0.36%

ROCE (Latest)

24.37%

ROE (Latest)

16.61%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 145 Schemes (42.56%)

Foreign Institutions

Held by 384 Foreign Institutions (31.06%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.21% vs 4.97% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -5.64% vs 6.22% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "806.00",
          "val2": "804.30",
          "chgp": "0.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "223.30",
          "val2": "216.70",
          "chgp": "3.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.90",
          "val2": "-4.10",
          "chgp": "-287.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "132.10",
          "val2": "140.00",
          "chgp": "-5.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "218.70%",
          "val2": "216.00%",
          "chgp": "0.27%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.29% vs -1.98% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.20% vs -16.97% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,074.70",
          "val2": "2,892.70",
          "chgp": "6.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "808.00",
          "val2": "750.00",
          "chgp": "7.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "2.90",
          "chgp": "-86.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-42.70",
          "val2": "-19.00",
          "chgp": "-124.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "493.70",
          "val2": "492.70",
          "chgp": "0.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "207.00%",
          "val2": "205.60%",
          "chgp": "0.14%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

806.00

804.30

0.21%

Operating Profit (PBDIT) excl Other Income

223.30

216.70

3.05%

Interest

0.00

0.10

-100.00%

Exceptional Items

-15.90

-4.10

-287.80%

Consolidate Net Profit

132.10

140.00

-5.64%

Operating Profit Margin (Excl OI)

218.70%

216.00%

0.27%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.21% vs 4.97% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -5.64% vs 6.22% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

3,074.70

2,892.70

6.29%

Operating Profit (PBDIT) excl Other Income

808.00

750.00

7.73%

Interest

0.40

2.90

-86.21%

Exceptional Items

-42.70

-19.00

-124.74%

Consolidate Net Profit

493.70

492.70

0.20%

Operating Profit Margin (Excl OI)

207.00%

205.60%

0.14%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 6.29% vs -1.98% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 0.20% vs -16.97% in Dec 2024

All Annual Results

Company CV

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.

Pharmaceuticals & Biotechnology

West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.

Company Coordinates

Company Details

530 HERMAN O WEST DR , EXTON PA : 19341-1147

Tel: 1 610 59429001 610 5943318

https://www.westpharma.com/

Registrar Details